Bay Area may be at risk from synthetic biology research labs
By Emily Smith Beitiks,
San Jose Mercury News
| 03. 27. 2012
Lawrence Berkeley National Laboratory recently announced a proposal to build a facility in Richmond at which synthetic biology research will be a major focus. This news should give us pause to consider exactly what risks this little-known field poses for the environment and human health.
Last year, molecular biologist Becky McClain was awarded $1.37 million in a whistle-blower suit against the pharmaceutical giant Pfizer after she was fired for raising safety concerns about the lab where she worked. McClain was infected with a genetically engineered virus being researched in her lab. She continues to experience intermittent paralysis and spinal pain, symptoms consistent with the effects of the pathogen.
McClain's story offers an important lesson for assessing a new kind of bioengineering: the rapidly growing field of synthetic biology, which has already been called genetic engineering on steroids.
Synthetic biologists build artificial organisms using the building blocks of life. While techniques vary, the intent is the same: to create life from scratch. Proponents promise extraordinary benefits, from curing diseases to replacing fossil fuels. But the unknowns are as serious as they...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...